Gilead se­cures first lenaca­pavir ap­proval in Eu­rope af­ter lengthy man­u­fac­tur­ing de­lays

Gilead is al­ready a leader among bio­phar­mas de­vel­op­ing drugs to coun­ter­act HIV, and a new de­ci­sion ear­ly Mon­day fur­ther ce­ment­ed its place.

The Eu­ro­pean Com­mis­sion has ap­proved Gilead’s lenaca­pavir for adults with mul­ti-drug re­sis­tant HIV, the com­pa­ny an­nounced, giv­ing the long-act­ing treat­ment its first green light. The drug, brand­ed as Sun­len­ca on the con­ti­nent, is de­signed to be ad­min­is­tered once every six months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER